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Abstract
Background: Human transmissible spongiform encephalopathies (HTSE), or Creutzfeldt-Jakob
disease (CJD), is a group of rare and fatal diseases in central nervous system. Since outbreak of
bovine spongiform encephalopathy (BSE) and variant CJD, a worldwide CJD surveillance network
has been established under the proposition of WHO. In China, a national CJD surveillance system
has started since 2002. The data of CJD surveillance from 2006 to 2007 was analyzed.
Methods: Total 12 provinces are included in CJD surveillance system. The surveillance unit in each
province consists of one or two sentinel hospitals and the provincial CDC. All suspected CJD cases
reported from CJD surveillance were diagnosed and subtyped based on the diagnostic criteria for
CJD issued by WHO.
Results: Total 192 suspected CJD cases were reported and 5 genetic CJD, 51 probable and 30
possible sporadic CJD (sCJD) cases were diagnosed. The collected sCJD cases distribute
sporadically without geographical clustering and seasonal relativity and the highest incidences in
both probable and possible sCJD cases appeared in the group of 60–69 year. The most common
three foremost symptoms were progressive dementia, cerebellum and mental-related symptoms.
The probable sCJD patients owning both typical EEG alteration and CSF protein 14-3-3 positive
have more characteristic clinical syndromes than the ones having only one positive. The
polymorphisms of codon 129 of all tested reported cases shows typical patterns of Han Chinese
as previous reports, that M129M are predominant whereas M129V are seldom.
Conclusion: Chinese CJD patients possessed similar epidemiological and clinical characteristics as
worldwide.
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Background
The description of human transmissible spongiform
encephalopathies (HTSE) which includes a group of rare,
fatal central nervous system disorders began with Creut-
zfeldt-Jakob disease (CJD), identified in the 1920s by two
German neuroscientists[1]. Four types of CJD named spo-
radic (sCJD), familial or genetic (gCJD), iatrogenic or acci-
dental (iCJD) and variant (vCJD) have been described.
The pathological agent of this kind of diseases, termed as
PrPSc, is believed to be an abnormal isoform of a cellular
prion protein, PrPC[2]. sCJD occurs spontaneously with
unknown aetiology and has no evidence of geographical
clustering. The incidence is generally between 0.5 and 1.5
cases per million persons per year and affects mainly the
elderly population. Mutations in the gene encoding PrPC
(PRNP) is known as gCJD[3]. iCJD is caused by exposure
to infectious prions through contaminated medical prod-
ucts such as biological materials and surgical instru-
ments[4]. vCJD is caused by consumption of
contaminated food through uptaking of bovine spongi-
form encephalopathy (BSE) prions[5].
Since the first ten vCJD cases were announced in the UK
in March, 1996, the geographical association with BSE
epidemic has been raised the possibility of a causal link.
Up to April, 2008, total 204 vCJD cases were found world-
wide, among them 166 cases were in UK including 115
cases died from definite vCJD, 48 cases died from proba-
ble vCJD without neuropathological confirmation and 3
are still alive [6]. In 2005, a vCJD case who had resided in
the UK for 24 days was identified in Japan[7]. As the great
impact of the outbreak of BSE and emerging of vCJD on
public health, WHO consultation recommended the
establishment of worldwide CJD surveillance in May,
1996. However, as the systematic surveillance for CJD has
only been undertaken in a minority of countries, the inci-
dence in much of the world area is currently unknown[8].
In China, the CJD surveillance system was established
under the framework of the surveillances for communica-
ble diseases led by Chinese Center for Disease Control
and Prevention (CCDC) since 2002 and became broader
in the past two years. The paper collects the surveillance
data from 2006 to 2007.
Methods
Construction of CJD surveillance system
China CJD surveillance started in 2002, which was con-
structed under the framework of national surveillance net-
work for communicable diseases led by CCDC. China has
31 provinces with a population of 1.3 billion. In CJD sur-
veillance system, total 12 provinces with the population
of 440 million were covered, including Beijing, Shanghai,
Tianjin, Chongqing, Jilin, Shaanxi, Hubei, Guangdong,
Guizhou, Anhui, Henan and Xinjiang. The surveillance
unit in each province consists of one or two sentinel hos-
pitals and the provincial CDC. The staff in the department
of neurology in the sentinel hospitals was responsible for
collecting the clinical data and sampling, while the staff
from provincial CDC took charge in collecting the epide-
miological data. The provincial CDC transferred all col-
lected data and samples to the national center, which is
the Department of Prion Disease, National Institute for
Viral Disease Control and Prevention, CCDC, for labora-
tory tests and final diagnosis. The clinical and epidemio-
logical data were collected by the formulized tables. The
clinical data included mainly general information, main
clinical manifestations, the first onset symptom, clinical
examinations (CT, MRI, EEG and routine cerebral spinal
fluid (CSF) biochemistry), specimen sampling data and
death data. The epidemiological data included the infor-
mation of inhabitancy, family history (mainly the demen-
tia), anamnesis (surgical or neurosurgical history, organ
transplantation, blood donation and transfusion, use of
extracts of pituitary or other blood products) and special
profession (medical staff, veterinary and butcher). The
clinical specimens collected for diagnosis of CJD were
brain tissues, CSF and blood. The national center feeds
back the diagnosis and the principles of management to
the provincial units. The surveillance and study was
approved by the Ethical Review Committee of China
CDC.
Case definition
All suspected CJD cases reported from CJD surveillance
were diagnosed and subtyped based on the diagnostic cri-
teria issued by CCDC, which was constituted based on the
diagnostic criteria for CJD issued by WHO[9]. The diagno-
sis for each case was made by an expert board consisting
of neurologists, neuropathologists, epidemiologists and
laboratory staff.
Laboratory tests
For CSF 14-3-3 protein assay, CSF was collected by routine
lumbar puncture during hospitalization. Western blots
for protein 14-3-3 in CSF were performed as the protocol
described elsewhere[10]. Briefly, 20 μl CSF sample was
separated by 12% SDS-PAGE and electronically trans-
formed onto nitrocellulose membrane. Blots were incu-
bated in 1:1000 diluted 14-3-3 polyclonal antibodies
(Santa Cruz, USA) and further incubated in 1:5000
diluted HRP-conjugated goat anti-Rabbit IgG (Perk-
inElmer, Germany). Immunoreactive bands were visual-
ized by ECL method (PerkinElmer, Germany).
For  PRNP  analysis, genomic DNA was extracted from
peripheral blood leukocytes by using Qiagen's DNA puri-
fication kit according to the manufacturer's instructions.
The PRNP open reading frame was amplified by polymer-
ase chain reaction (PCR) using a protocol and primers
described elsewhere[11]. The genotype at codon 129 ofBMC Public Health 2008, 8:360 http://www.biomedcentral.com/1471-2458/8/360
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PRNP was determined by digestion with the restriction
endonuclease NspI. Analysis of PRNP sequences was per-
formed by direct sequencing in a MacBAC sequencer
(Pharmacia, USA).
For neuropathological assay, slides of brains were ana-
lyzed by HE staining. The immunohistochemistry stain-
ing for PrPSc  were performed using PrP specific
monoclonal antibody 3F4 (Dako) as the primary anti-
body. Western blots for PrPSc was conducted according to
the protocol described previously[12]. Briefly, Brain tissue
sample was homogenized in 9 volumes of lysis buffer
(100 mM NaCl, 10 mM EDTA, 0.5% Nonidet P-40, 0.5%
sodium deoxycholate, 10 mM Tris, pH 7.5). Aliquot of the
brain homogenate was incubated with 50 μg/ml protein-
ase K (PK) at a final concentration at 37°C for 1 h. Sam-
ples were separated in 15% SDS-PAGE and electronically
transferred to nitrocellulose membrane. The membrane
was incubated with 1:5,000 diluted antibody 3F4 (Dako)
and further incubated in 1:5000 diluted HRP-conjugated
goat anti-Mouse IgG (Santa Cruz, USA).
Statistic analysis
All statistical analyses were performed using the SPSS 11.5
computer software programme.
Results
From 2006 to 2007, total 192 suspected CJD cases were
reported through CJD surveillance system. All reported
cases were Han Chinese. After carefully analyzed the clin-
ical, epidemiological and laboratory data, 51 patients
were diagnosed as the probable sCJD cases, 30 were pos-
sible sCJD cases based on the diagnosis criteria. In addi-
tion, two fatal familial insomnia (FFI) cases in one family
and 3 gCJD cases, G114V, T188K and E200K, were defi-
nitely diagnosed with the evidences of PrPSc in brain sam-
ples and/or special mutations in PRNP. Among them, two
FFI cases and the G114V case had autopsy and were diag-
nosed as definite gCJD based on the neuropathological
assays and Western blots. For every reported case, a well-
regulated follow-up survey was carried out and registered
individually, especially the patients with 14-3-3 protein
positive in CSF. The final diagnoses of 29 non-CJD cases
with positive 14-3-3 protein included 3 viral encephalitis,
1 syphilitic encephalitis, 2 tuberculosis encephalitis, 1
encephalomeningitis, 1 allergic encephalitis, 1 myelinoc-
lasis, 2 neurodegenerative disease and 1 paraneoplastic
syndrome. The rests discharged from hospitals without
final definite diagnosis.
General epidemiological data
The onset ages of 51 probable sCJD cases varied from 33
to 74 years old, with the mean age of 60.2 years, and the
onset ages of 30 possible sCJD were from 37 to 78 years
old, with mean age of 60.4 years. The highest incidences
were in the group of 60–69 year-old in both probable and
possible sCJD cases (Fig 1). In contrast, the onset ages of
5 gCJD patients were from 26 to 63, with mean ages of
The age distribution of probable and possible sCJD cases from 2006 to 2007 Figure 1
The age distribution of probable and possible sCJD cases from 2006 to 2007. The black column indicates probable 
sCJD, the grey column indicates possible sCJD and the curve represents the total numbers.
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48.2 years. The male to female ratio was 35:16 in probable
sCJD and 20:10 in possible sCJD.
The resident places of probable and possible sCJD cases
were diffused in 23 different provinces in China, although
Beijing and Shanghai reported more cases than other
provinces. The occupations of probable and possible sCJD
cases were also various, including workers, farmers, teach-
ers, officials, self-employees and house-wives. Three cases
were medical staffs before retired, but after careful investi-
gation, we excluded the possibility of iatrogenic infection.
All probable and possible cases showed no linkage with
their anamnesis. Additionally, the suspected CJD cases
were reported around all year, without seasonal specifi-
city.
Clinical data
The foremost symptoms of the reported sCJD cases were
multifarious. Progressive dementia was the most familiar
one that was described by 35 out of 81 (43.2%) patients.
Other commonly observed clinical manifestations
included mental-related syndromes (22/81, 27.2%), cere-
bellum-related syndromes (16/81, 19.6%), pyramidal or
extrapyramidal disfunction (12/81, 14.8%), slow progres-
sive dementia (8/81, 9.9%). Additionally, nine patients
complained with visual disturbance, three with cerebral
stroke-like symptoms without confirmation of ischemia,
and rest three patients with dizziness, sleeping distur-
bance or lower limbs inability (Table 1).
According to the diagnosis criteria, CJD must have pro-
gressive dementia and at least two of the following four
clinical features, myoclonus, visual or cerebellar distur-
bance, pyramidal or extrapyramidal disfunction and aki-
netic mutism. Calculation of the presences of the four
other manifestations among 81 sCJD cases identified that
in the group of probable sCJD the most common symp-
tom was pyramidal or extrapyramidal disfunction
(84.3%), followed by myoclonus (78.4%), visual or cere-
bellar disturbance (68.6%) and akinetic mutism (47.1%),
whereas in the group of possible sCJD the most common
one was also pyramidal or extrapyramidal disfunction
(86.7%), followed by myoclonus (70.0%), visual or cere-
bellar disturbance (70.0%) and akinetic mutism (50.0%)
(Table 2). The appearance of common symptoms
between probable and possible sCJD had no statistic dif-
ference, the p value showed in the table.
Analysis of the frequency of the four major manifestations
in sCJD showed that besides progressive dementia, large
portion of the patients had two other clinical symptoms,
followed by having three and four (Table 3). The distrib-
uting frequency of the main clinical symptoms between
probable and possible sCJD were quite similar, without
statistic difference, the p value showed in the table.
Laboratory tests
Among 192 reported cases, 182 cases had the tests of pro-
tein 14-3-3 in CSF and 91 cases had EEG examinations. 65
CSF samples were 14-3-3 positive and 47 cases showed
typical periodic sharp wave complexes (PSWC) on the
EEG. Among 51 cases diagnosed as probable sCJD, 20
developed both CJD-specific EEG alternations and posi-
tive 14-3-3 in CSF, 16 were 14-3-3 positive only and 15
had EEG changes only. Comparative analyses of the
emerges of the clinical manifestations showed that myo-
clonus was identified in all patients with both 14-3-3 pos-
itive and EEG change, while appearance frequencies of
visual or cerebellar disturbance and akinetic mutism in
this group were higher than that in the groups of 14-3-3
positive only and of EEG change only (Table 4). Most of
the patients (93.8%) in the group of 14-3-3 positive only
showed pyramidal or extrapyramidal disfunction, which
was much higher than the other two groups. It highlights
that the appearances of clinical manifestations may corre-
late with the phenotypes of laboratory examinations in
sCJD patients. The patients with both 14-3-3 positive and
EEG change seem to have more clinical symptoms. By sta-
tistic analyses, there was no difference in visual or cerebel-
lar disturbance, pyramidal or extrapyramidal disfunction
and akinetic mutism symptoms, but significant difference
in myoclonus symptom among the three groups (p =
0.006, Table 4).
Analyses of PRNP from 135 patients reported in CJD sur-
veillance revealed again that most cases (131, 97.0%)
were methionine homozygous genotype at codon 129,
four (3.0%) were methionine/valine heterozygosity and
none was valine/valine homozygous, which correspond-
ing well with our previous results[13]. The polymorphism
of codon 129 showed the same pattern in probable and
possible sCJD patients, that in 48 tested probable cases 45
Table 1: The foremost symptoms of the probable and possible 
sCJD patients
clinical manifestation case number
progressive dementia 35 (43.2%)
mental syndrome1 22 (27.2%)
cerebellum syndrome 16 (19.8%)
pyramidal or extrapyramidal disfunction 12 (14.8%)
visual disturbance 9 (11.1%)
slow progressive dementia2 8 (9.9%)
cerebral stroke 3 (3.7%)
dizziness 1 (1.2%)
sleeping disturbance 1 (1.2%)
lower limbs inability 1 (1.2%)
clinical manifestation case number
1: including sleeping turbulence, depression, anxiety and stress etc.
2: when the dementia persists longer than one year progressively 
without other manifestationsBMC Public Health 2008, 8:360 http://www.biomedcentral.com/1471-2458/8/360
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were M/M and 3 were M/V, and all 24 tested possible cases
were M/M genotypes. The genotypes of codon 129 of
three gCJD cases were all M/M.
Discussion
Since German neurologists Creutzfeldt and Jakob firstly
reported the cases with progressive cerebral dysfunction,
the 'Creutzfeldt-Jakob disease' has been known for almost
one century. Since the occurrence of vCJD in Europe was
addressed, WHO consultation had recommended the
establishment of worldwide CJD surveillance[14]. In
2002, China started to set up the national CJD surveil-
lance and join into the worldwide surveillance system. It
consists of twelve provinces now with about 440 millions
inhabitants. In this paper, we propose the surveillance
results from 2006 to 2007. Except five genetic CJD cases,
all CJD cases are diagnosed as sCJD. No iCJD and vCJD
has been identified. The collected sCJD cases distribute
sporadically without geographical clustering. The mean
onset ages of the probable sCJD and possible sCJD cases
are almost the same, showing the highest incidence in the
group of 60–69 years. There are more male cases than
female ones in the past two years, probably reflecting only
short-term surveillance.
Many symptoms have been described as the foremost
clinical manifestations in sCJD patients. The first three
common symptoms are progressive dementia, cerebellum
and mental-related symptoms. Along with the progres-
sion of the disease, more neurological symptoms have
been identified, among them progressive dementia has
been observed sooner or later in all sCJD patients. No dif-
ferences in the appearances and frequencies of other four
main clinical manifestations have been notified in the
groups of probable sCJD and possible sCJD.
EEG examination and CSF protein 14-3-3 test are the
indexes for probable sCJD according to the diagnostic cri-
teria recommended by WHO[9]. We find that the proba-
ble sCJD patients owning both typical EEG alteration and
CSF protein 14-3-3 positive have more characteristic clin-
ical syndromes than the ones having only one positive.
Meanwhile, all cases with 14-3-3 positive and EEG alther-
ation show myoclonus during their clinical courses. CSF
14-3-3 positive is believed as the marker of brain dam-
age[15]. EEG abnormality represents early recognition of
worsening brain function[16]. It might reflect that the
patients owning two positive results have more patholog-
ical changes in brains.
In our surveillance system, the PRNP genes of all reported
cases have been screened if available. The polymorphisms
of codon 129 of all tested reported cases show typical pat-
terns of Han Chinese as previous reports[13], that M129M
are predominant whereas M129V are seldom. Addition-
ally, analyses of a few biopsy and postmortem brain sam-
ples of sCJD cases collected previously show all type 1
PrPSc patterns in Western blots (unpublished data). All
these patients have been confirmed to be M129M
homozygous. Furthermore, five genetic CJD cases have
been identified through CJD surveillance. Two cases,
T188K and E200K, do not have detectable family histo-
ries, which are reported and primarily diagnosed as prob-
able and possible sCJD, respectively. It emphasizes that
PRNP gene sequencing is essential and unique for detec-
tion of gCJD without detectable family history.
Although CJD cases have been identified through our CJD
surveillance, the reported and diagnosed cases is far from
the expected one based on the numbers of inhabitants.
Therefore, it is hard to line out the morbidity of CJD in
China. Lack of knowledge of this rare disease in local cli-
nicians in small town encumbers the sensitivity of surveil-
lance system. Carefully designed training programs will
help to improve this situation. Compared with the devel-
oped countries, the rate of postmortem is extremely lower
Table 2: The appearances of main clinical manifestations in probable and possible sCJD patients
cases number progressive dementia myoclonus visual or cerebellar 
disturbance
pyramidal or extrapyramidal 
disfunction
akinetic mutism
Probable sCJD 51 51 (100%) 40 (78.4%) 35 (68.6%) 43 (84.3%) 24 (47.1%)
Possible sCJD 30 30 (100%) 21(70.0%) 21(70.0%) 26(86.7%) 15(50.0%)
P 0.395 0.897 0.773 0.798
Table 3: The frequencies of other four clinical manifestations except progressive dementia in probable and possible sCJD patients
Case number Having four clinical features Having three clinical features Having two clinical features
Probable sCJD 51 11 (21.6%) 17 (33.3%) 20 (45.1%)
Possible sCJD 30 7 (23.3%) 10 (33.3%) 16 (43.3%)
P 0.854 1.000 0.217BMC Public Health 2008, 8:360 http://www.biomedcentral.com/1471-2458/8/360
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in China, due to the traditional customs. Therefore, apart
from the future legislation for brain autopsy of suspected
CJD patient, enhancing follow-up will improve the qual-
ity of our CJD surveillance system.
Conclusion
The results of the present study revealed the general epide-
miology status of CJD in China from 2006 to 2007. Fore-
most clinical manifestations were different among the
CJD patients, but along with the progression of the dis-
ease, progressive dementia was observed sooner or later in
all cases. EEG examination, CSF protein 14-3-3 test and
PRNP gene analyses were the main laboratory tools for the
suspected patients without postmortem. M129M were the
predominant genotype in Han Chinese. The morbidity of
CJD in China still remained unsettled for the short-term
surveillance. Due to the lower rate of postmortem,
enhancing follow-up will improve the quality of the CJD
surveillance system.
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Table 4: Comparison of the results of 14-3-3 and EEG with the appearances of clinical manifestations in probable sCJD patients
cases number progressive dementia myoclonus visual or cerebellar 
disturbance
pyramidal or extrapyramidal 
disfunction
akinetic mutism
14-3-3 positive 16 16 (100%) 9 (56.3%) 9 (56.3%) 15 (93.8%) 6 (37.5%)
EEG changes 15 15 (100%) 11 (73.3%) 10 (66.7%) 13 (66.7%) 7 (46.7%)
14-3-3 + EEG 20 20 (100%) 20 (100%) 16 (80.0%) 15 (75.0%) 11 (55.0%)
p 0.006 0.306 0.293 0.579